Immunovant, Inc.
IMVT
Updated: 25/09/2026, 09:53:48
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
No summaries found.
- Share price
- $34.00
- Market cap
- $7.02B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Eric Venker
- Employees
- 315
- IPO date
- 21/06/2019
- Beta
- 0.8100000000000001
- Last dividend
- $0.00
- Day range
- $33.37 – $34.55
- 52-week range
- $15.56 – $45.42
- 1-day performance
- -1.56%
- 1-year performance
- 118.57%
- Current drawdown (1Y)
- -25.14%
- CIK
- 0001764013
- CUSIP
- 45258J102
- ISIN
- US45258J1025
- Created
- 07/12/2025, 04:43:36
- Last update
- 25/09/2026, 09:53:48
Track Immunovant, Inc. with an AI analyst
See which prediction-market events move IMVT, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
Zacks Investment Research • STOCK • 12/06/2026, 13:11:00
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Seeking Alpha • STOCK • 25/05/2026, 08:27:31
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Seeking Alpha • STOCK • 21/05/2026, 15:09:35
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Zacks Investment Research • STOCK • 21/05/2026, 12:20:56
Immunovant Q4 Earnings Call Highlights
MarketBeat • STOCK • 20/05/2026, 12:08:52
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Zacks Investment Research • STOCK • 06/04/2026, 16:10:38
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Seeking Alpha • STOCK • 02/04/2026, 18:32:03
Immunovant's treatment for eye disease fails late-stage trial
Reuters • STOCK • 02/04/2026, 07:06:08
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
GlobeNewsWire • STOCK • 02/04/2026, 07:00:00
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
The Motley Fool • STOCK • 15/03/2026, 16:39:36
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
Zacks Investment Research • STOCK • 05/03/2026, 14:41:08
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
PRNewsWire • STOCK • 17/02/2026, 11:48:00